Citi lowered the target price for CSPC Pharma (01093) to HKD10 from HKD13 and maintained the "buy" rating.
The research house said it cuts FY24/25/26 revenue forecasts by 9%/17%/22% to factor in oncology sales decline and slower than expected innovative sales.
《說說心理話》【奧運劍擊熱】大師兄張小倫親身分享!贏在起跑線=壓力?如何培育子女有卓越成就?► 即睇